A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
INTERPACE BIOSCIENCES, INC.
IDXG
$39M
Mkt Cap
$1.46
+0.69%
INTERPACE BIOSCIENCES, INC. (IDXG) has a 5-year average return on invested capital (ROIC) of 34.5%. This indicates strong capital allocation and a potential competitive advantage.
INTERPACE BIOSCIENCES, INC. (IDXG) has a market capitalization of $39M. It is classified as a small-cap stock.
INTERPACE BIOSCIENCES, INC. (IDXG) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.05%.
INTERPACE BIOSCIENCES, INC. (IDXG) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
INTERPACE BIOSCIENCES, INC. (IDXG) reported annual revenue of $39 million in its most recent fiscal year, based on SEC EDGAR filings.
INTERPACE BIOSCIENCES, INC. (IDXG) has a net profit margin of 63.5%. This is a strong margin indicating high profitability.
INTERPACE BIOSCIENCES, INC. (IDXG) generated $5 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Company Overview We are a company that provides esoteric molecular diagnostic testing, and pathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer from clinical features. We develop and commercialize genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. Customer Category Types of Customers Nature of Services Clinical services ● Hospitals ● Physicians ● Cancer Centers ● Clinics Clinical services that help guide patient management decisions by providing information on the diagnosis and prognosis of indeterminate specimens. Guidance on genetic marker-related pharmaceutical treatment options, when available, is also provided.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 39M | 39M | 47M | 40M | 32M | 33M |
| Net Income | 25M | 25M | 6.2M | 2.0M | -22M | -15M |
| EPS | $0.92 | $0.92 | $0.24 | $0.08 | $-0.86 | $-0.60 |
| Free Cash Flow | 5.5M | 5.5M | 3.8M | 3.3M | -8.0M | -9.1M |
| ROIC | 109.1% | 117.2% | 58.1% | 27.0% | -13.3% | -16.5% |
| Gross Margin | 62.3% | 62.3% | 63.8% | 62.6% | 57.3% | 56.8% |
| Debt/Equity | 0.25 | 0.25 | -2.92 | -0.14 | -0.08 | -0.10 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | 4.1M | 4.1M | 8.1M | 4.0M | -3.6M | -6.3M |
| Operating Margin | 10.5% | 10.5% | 17.3% | 9.9% | -11.4% | -19.1% |
| ROE | 109.9% | 244.0% | -21.6% | -3.4% | 43.7% | 41.8% |
| Shares Outstanding | 27M | 27M | 26M | 26M | 25M | 25M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 120M | 9.4M | 13M | 16M | 22M | 24M | 32M | 33M | 32M | 40M | 47M | 39M | 39M |
| Gross Margin | 0.2% | 26.7% | 49.2% | 53.7% | 53.4% | 34.4% | 33.1% | 56.8% | 57.3% | 62.6% | 63.8% | 62.3% | 62.3% |
| R&D | 255K | 2.3M | 1.6M | 1.5M | 2.1M | 2.8M | 2.8M | 1.5M | 703K | 636K | 676K | 642K | 642K |
| SG&A | 14M | 17M | 11M | 9.2M | 8.7M | 14M | 18M | 11M | 11M | 9.4M | 9.5M | 9.5M | 9.5M |
| EBIT | -18M | -40M | -6.4M | -6.3M | -13M | -26M | -26M | -6.3M | -3.6M | 4.0M | 8.1M | 4.1M | 4.1M |
| Op. Margin | -14.9% | -428.4% | -49.2% | -39.6% | -57.7% | -109.1% | -80.5% | -19.1% | -11.4% | 9.9% | 17.3% | 10.5% | 10.5% |
| Net Income | N/A | N/A | N/A | 13M | -13M | -27M | -29M | -15M | -22M | 2.0M | 6.2M | 25M | 25M |
| Net Margin | N/A | N/A | N/A | 79.0% | -58.0% | -112.2% | -91.0% | -45.1% | -69.0% | 4.9% | 13.3% | 63.5% | 63.5% |
| Non-Recurring | 1.4M | 41M | 13M | 5K | 0 | 0 | 37K | -13K | 8.4M | 0 | 0 | 898K | 898K |
| Returns on Capital | |||||||||||||
| ROIC | N/A | N/A | N/A | 100.5% | -59.6% | N/M | -57.1% | -16.5% | -13.3% | 27.0% | 58.1% | 117.2% | 109.1% |
| ROE | N/A | N/A | N/A | 196.4% | -66.3% | -495.5% | 175.7% | 41.8% | 43.7% | -3.4% | -21.6% | 244.0% | 109.9% |
| ROA | N/A | N/A | N/A | 40.7% | -37.5% | -65.7% | -60.7% | -35.5% | -80.7% | 13.4% | 44.7% | 101.1% | 72.6% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -16M | -20M | -7.6M | -15M | -8.7M | -19M | -14M | -8.7M | -7.7M | 3.8M | 4.6M | 5.8M | 5.8M |
| Free Cash Flow | -19M | -20M | -7.6M | -15M | -9.1M | -19M | -16M | -9.1M | -8.0M | 3.3M | 3.8M | 5.5M | 5.5M |
| Owner Earnings | -21M | -29M | -12M | -20M | -15M | -25M | -22M | -15M | -12M | 2.1M | 4.1M | 5.4M | 5.4M |
| CapEx | 2.9M | 353K | 0 | 29K | 449K | 131K | 1.6M | 354K | 322K | 470K | 876K | 356K | 356K |
| Maint. CapEx | 2.4M | 5.0M | 4.5M | 3.7M | 3.8M | 4.5M | 5.5M | 5.4M | 2.6M | 1.0M | 300K | 425K | 425K |
| Growth CapEx | 460K | 0 | N/A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 576K | 0 | 0 |
| D&A | 2.4M | 5.0M | 4.5M | 3.7M | 3.8M | 4.5M | 5.5M | 5.4M | 2.6M | 1.0M | 300K | 425K | 425K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 6.1% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 228K | 208K | 0 | 0 | 9K | 41K | 52K | 0 | 108K | 32K | 46K | 18K | 18K |
| Buyback Yield | 0.0% | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 2.1M | 4.0M | 131K | 1.1M | 2.3M | 1.5M | 2.2M | 1.3M | 1.3M | 630K | 291K | 35K | 35K |
| Debt Repayment | 0 | 20M | 1.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | 3.9M | -19K | 6.0M | -11M | N/A | 8.8M | 6.7M | 1.4M | 24K | 4.3M | 5.0M | 3.1M | 3.1M |
| Cash & Equiv. | 23M | 8.3M | 602K | 15M | 6.1M | 2.3M | 2.8M | 2.7M | 4.8M | 3.5M | 1.5M | 2.5M | 2.5M |
| Long-Term Debt | 27M | 7.2M | 7.9M | 4.3M | N/A | 2.7M | 3.7M | 520K | 1.8M | 896K | 625K | 168K | 168K |
| Debt/Equity | 1.40 | 0.83 | -0.65 | 0.19 | 1.02 | -2.49 | -0.32 | -0.10 | -0.08 | -0.14 | -2.92 | 0.25 | 0.25 |
| Interest Coverage | -29.6 | -10.9 | -3.0 | -14.5 | -38.2 | -60.1 | -47.5 | -31.7 | -4.3 | 4.4 | 20.3 | 10.2 | 10.2 |
| Equity | 19M | 10M | -10M | 23M | 15M | -4.5M | -29M | -42M | -58M | -56M | -2.2M | 22M | 22M |
| Total Assets | 115M | 65M | 25M | 37M | 31M | 52M | 46M | 38M | 16M | 13M | 15M | 34M | 34M |
| Total Liabilities | 96M | 55M | 19M | 14M | 16M | 30M | 28M | 34M | 74M | 69M | 17M | 11M | 11M |
| Intangibles | 47M | 43M | N/A | 33M | 13M | 16M | 11M | 2.1M | 861K | 544K | N/A | N/A | N/A |
| Retained Earnings | -100M | -111M | -120M | -132M | -159M | -186M | -212M | -227M | -249M | -242M | -235M | -211M | -211M |
| Working Capital | 11M | -4.2M | -12M | 12M | 9.1M | -782K | -4.1M | -3.5M | -2.1M | -1.0M | 1.2M | 4.8M | 4.8M |
| Current Assets | 45M | 19M | 4.2M | 20M | 18M | 17M | 14M | 12M | 12M | 10M | 12M | 9.9M | 9.9M |
| Current Liabilities | 34M | 23M | 16M | 8.1M | 8.7M | 17M | 18M | 16M | 14M | 11M | 11M | 5.1M | 5.1M |
| Per Share Data | |||||||||||||
| EPS | -506.39 | -395.78 | -544.05 | 0.68 | -6.78 | -10.88 | -1.22 | -0.60 | -0.86 | 0.08 | 0.24 | 0.92 | 0.92 |
| Owner EPS | -6.12 | -73.60 | -25.27 | -1.08 | -7.87 | -10.01 | -0.90 | -0.62 | -0.45 | 0.08 | 0.15 | 0.20 | 0.20 |
| Book Value | 5.69 | 25.65 | -20.91 | 1.23 | 8.24 | -1.79 | -1.20 | -1.71 | -2.28 | -2.13 | -0.08 | 0.84 | 0.84 |
| Cash Flow/Share | -4.80 | -50.55 | -15.73 | -0.82 | -4.63 | -7.59 | -0.58 | -0.35 | -0.30 | 0.15 | 0.18 | 0.22 | 0.94 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 3.4M | 0.4M | 0.5M | 18.6M | 1.9M | 2.5M | 24.2M | 24.8M | 25.4M | 26.1M | 26.5M | 26.6M | 26.6M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 7.1 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 10.3 |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.7 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.0 |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 14.1% |
| Market Cap | 0 | 0 | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 | 0 | 39M |
| Avg. Price | 0.00 | 0.00 | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 | 1.46 |
| Year-End Price | 0.00 | 0.00 | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 | 1.46 |
INTERPACE BIOSCIENCES, INC. passes 5 of 9 quality checks, suggesting mixed fundamentals.
The company's 5-year average ROIC is 34.5% with a gross margin of 60.5%.
INTERPACE BIOSCIENCES, INC. (IDXG) has a debt-to-equity ratio of 0.25. This indicates a conservatively financed balance sheet.
INTERPACE BIOSCIENCES, INC. (IDXG) reported earnings per share (EPS) of $0.92 in its most recent fiscal year.
INTERPACE BIOSCIENCES, INC. (IDXG) has a return on equity (ROE) of 244.0%. This indicates the company generates strong returns for shareholders.
INTERPACE BIOSCIENCES, INC. (IDXG) has a 5-year average gross margin of 60.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for INTERPACE BIOSCIENCES, INC. (IDXG), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
INTERPACE BIOSCIENCES, INC. (IDXG) has a book value per share of $0.84, based on its most recent annual SEC filing.
No recent press releases.